/FW

Approved for use through 04/30/2003. OMB 0651-0031

Onder the Paperwork Reduction Act of 1995, no		n of information unless	se it displays a valid OMB control number.									
TRANSMITTAL	Filing Date	10/724,856	002									
JUN 0 1 2004 JUN FORM	First Named Inventor	December 1, 20										
2. #/	A-110-24	Donald E. Frai	ll									
(to be used for all correspondence after initial filing												
(to be used for all correspondence after initial filing	Examiner Name											
Total Number of Pages in This Submission	Attorney Docket Number	01458.US1										
ENCLOSURES (Check all that apply)												
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s)	to C App of A App (App (App Pro Stat Ch Iden A return-re										
Response to Missing Parts under 37 CFR 1.52 or 1.53												
SIGNATU	RE OF APPLICANT, ATTORN	EY, OR AGENT	Γ									
Firm or Individual name Pharmacia & Upjohn Co	ompany											
Date May 28, 2004	May 28, 2004											
CER	TIFICATE OF TRANSMISSION	/MAII ING										
I hereby certify that this correspondence is being sufficient postage as first class mail in an envelo the date shown below.	facsimile transmitted to the USPTO or	deposited with the										
Typed or printed name Julie K. Lyons												
Signature yeal: E.K.	-cons		Date May 28, 2004									

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUN 0 1 2004 LET OF REFERENCES CITED BY APPLICANT RAGE (18) several sheets if necessary)			Atty. Docket No. 01458.US1			Serial No. 10/724,856				
	(R) BE			Applicant	l	- -	-			
					Filing Date 12/01/2003			Group		
			U.S. PA	ATENT DOCUM	ENTS		<u> </u>			
Examiner Initial		Document Number	Date	Name Class Subclass		Filing Date If Appropriate				
	AA	US 4,375,471	February 19, 1981	Richard C. Effland et al		424	258			
			FOREIGN	PATENT DOCU	JMENTS					
H 44 A A A		Document Number	Date	Country		Class	Subclass	Translation		
			_					Yes	No	
	AB	EP 0330360	February 14, 1989	Europe		C07D	217/14			
	ACE	WO 97/23458	December 20, 1996	World		C07D	211/06			
	AD	WO 01/32624	November 3, 1999	World		C07D	217/04			
	AE	WO 01/32625	November 3, 2000	World		C07D	217/04			
	*	C	OTHER PRIOR ART (Inc	cluding Author, Title,	Date, Pertinent F	Pages, Etc.)				
	AF	G.Stille, Arzn. Fo	orsch. 14, 534-537, 1964	ļ						
	AG	S. Diamond, et al," Chronic tension headache treated with amitruptyline: a double blind study", Headache 11:110-116, 1971								
	AH	T. Higuchi and V. Stella, "Pro-drugs as Novel Drug Delivery Systems", Vol 14 of the A.C.S. Symposium American Chemical Society, 1974								
	AI J.R. Couch, et al.," Amitriptyline in the prophylaxis of migraine", Neurology 26:121-127, 1976 AJ S. M. Berge, et al, "Pharmaceutical Salts," J. Pharm. Sci, 66: P.1-19 (1977)							3		
) -	
	AK N. Nakeya et al , Chem Pharm. Bull., , 32, P.692, 1984									
	AL "Remington's Pharmaceutical Sciences", 17th ed., Mack Publishing Company, Easton, PA							85		
_	AM H. Bundgaard , "Design of Prodrugs", Ed., Elsevier, 1985									
	AN	K. Widder et al, "Methods in Enzymology", , Ed., Academic Press, 421, P.309-396, 1985								
	AO	Edward B. Roche, "Bioreversible Carriers in Drug Design", American Pharmaceutical Association and Pergamon Press, 1987								
	AR Journal of Pharmaceutical Sciences, 77, P. 285, 1988									
	AS "Design and Applications of Prodrugs" P. 113-191, 1991									
	AT	H. Bundgard Advanced Drug Delivery Reviews, , 8, P. 1-38, 1992								
	AU E. Shen, GM Cooke, RA Horlick, Gene 156: 235-239, 1995									
Examiner	Examiner				Date Considered					
				1						